Cisplatin transiently up-regulates hHR23 expression through enhanced translational efficiency in A549 adenocarcinoma cells

Toxicology Letters

Volumn 205, Issue 3, 2011, Pages 341-350

  Shen, Yu Han ^a   Chen, Bo Rong ^a   Cherng, Shur Hueih ^b   Chueh, Pin Ju ^a   Tan, Xiaoton ^a   Lin, Yun Wei ^c   Lin, Jin Ching ^d   Chuang, Show Mei ^a  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b HUNGKUANG UNIVERSITY   (Taiwan)

^c NATIONAL CHIAYI UNIVERSITY   (Taiwan)

^d TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Cancer; Cisplatin; Cytotoxicity; DNA repair; HHR23

Indexed keywords

BINDING PROTEIN; CISPLATIN; DNA; HHR23 PROTEIN; HHR23B PROTEIN; INITIATION FACTOR 4B; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEOTIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P21; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP C PROTEIN;

ARTICLE; ATTENUATION; CARCINOMA CELL; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; ENZYME INHIBITION; EXCISION REPAIR; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LOW DRUG DOSE; LUNG ADENOCARCINOMA; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; RECEPTOR UPREGULATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DNA REPAIR; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; EUKARYOTIC INITIATION FACTORS; HUMANS; LUNG NEOPLASMS; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTEIN BIOSYNTHESIS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS P21(RAS); RNA INTERFERENCE; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 79960900478     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2011.06.028     Document Type: Article

References (30)

1. Altaha R., Liang X., Yu J.J., Reed E. Excision repair cross complementing-group 1: gene expression and platinum resistance. Int. J. Mol. Med. 2004, 14:959-970.
2. Brignone C., Bradley K.E., Kisselev A.F., Grossman S.R. A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway. Oncogene 2004, 23:4121-4129.
3. Chen L., Madura K. Evidence for distinct functions for human DNA repair factors hHR23A and hHR23B. FEBS Lett. 2006, 580:3401-3408.
4. Cortes-Sempere M., Chattopadhyay S., Rovira A., Rodriguez-Fanjul V., Belda-Iniesta C., Tapia M., Cejas P., Machado-Pinilla R., Manguan-Garcia C., Sanchez-Perez I., Nistal M., Moratilla C., de Castro-Carpeno J., Gonzalez-Baron M., Albanell J., Perona R. MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer. Cancer Lett. 2009, 286:206-216.
5. De Silva I.U., McHugh P.J., Clingen P.H., Hartley J.A. Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol. Cell. Biol. 2000, 20:7980-7990.
6. Ferry K.V., Hamilton T.C., Johnson S.W. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem. Pharmacol. 2000, 60:1305-1313.
7. Friedberg E.C., Wallner G., Siede C.W. DNA Repair and Mutagenesis 1995, ASM Press, Washington.
8. Furuta T., Ueda T., Aune G., Sarasin A., Kraemer K.H., Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res. 2002, 62:4899-4902.
9. Glockzin S., Ogi F.X., Hengstermann A., Scheffner M., Blattner C. Involvement of the DNA repair protein hHR23 in p53 degradation. Mol. Cell. Biol. 2003, 23:8960-8969.
10. Kaur M., Pop M., Shi D., Brignone C., Grossman S.R. hHR23B is required for genotoxic-specific activation of p53 and apoptosis. Oncogene 2007, 26:1231-1237.
11. Koberle B., Masters J.R., Hartley J.A., Wood R.D. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr. Biol. 1999, 9:273-276.
12. Lebwohl D., Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur. J. Cancer 1998, 34:1522-1534.
13. Li L., Lu X., Peterson C., Legerski R. XPC interacts with both HHR23B and HHR23A in vivo. Mutat. Res. 1997, 383:197-203.
14. Lin Y.W., Chuang S.M., Yang J.L. Persistent activation of ERK1/2 by lead acetate increases nucleotide excision repair synthesis and confers anti-cytotoxicity and anti-mutagenicity. Carcinogenesis 2003, 24:53-61.
15. Martin L.P., Hamilton T.C., Schilder R.J. Platinum resistance: the role of DNA repair pathways. Clin. Cancer Res. 2008, 14:1291-1295.
16. Ng J.M., Vermeulen W., van der Horst G.T., Bergink S., Sugasawa K., Vrieling H., Hoeijmakers J.H. A novel regulation mechanism of DNA repair by damage-induced and RAD23-dependent stabilization of xeroderma pigmentosum group C protein. Genes Dev. 2003, 17:1630-1645.
17. Niedernhofer L.J., Odijk H., Budzowska M., van Drunen E., Maas A., Theil A.F., de Wit J., Jaspers N.G., Beverloo H.B., Hoeijmakers J.H., Kanaar R. The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol. Cell. Biol. 2004, 24:5776-5787.
18. Okuda Y., Nishi R., Ng J.M., Vermeulen W., van der Horst G.T., Mori T., Hoeijmakers J.H., Hanaoka F., Sugasawa K. Relative levels of the two mammalian Rad23 homologs determine composition and stability of the xeroderma pigmentosum group C protein complex. DNA Repair (Amst.) 2004, 3:1285-1295.
19. Rabik C.A., Dolan M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev. 2007, 33:9-23.
20. Sargent R.G., Meservy J.L., Perkins B.D., Kilburn A.E., Intody Z., Adair G.M., Nairn R.S., Wilson J.H. Role of the nucleotide excision repair gene ERCC1 in formation of recombination-dependent rearrangements in mammalian cells. Nucleic Acids Res. 2000, 28:3771-3778.
21. Selvakumaran M., Pisarcik D.A., Bao R., Yeung A.T., Hamilton T.C. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res. 2003, 63:1311-1316.
22. Stordal B., Davey R. ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair. Cancer Chemother. Pharmacol. 2009, 63:661-672.
23. Sugasawa K., Masutani C., Uchida A., Maekawa T., van der Spek P.J., Bootsma D., Hoeijmakers J.H., Hanaoka F. HHR23B, a human Rad23 homolog, stimulates XPC protein in nucleotide excision repair in vitro. Mol. Cell. Biol. 1996, 16:4852-4861.
24. Sugasawa K., Ng J.M., Masutani C., Maekawa T., Uchida A., van der Spek P.J., Eker A.P., Rademakers S., Visser C., Aboussekhra A., Wood R.D., Hanaoka F., Bootsma D., Hoeijmakers J.H. Two human homologs of Rad23 are functionally interchangeable in complex formation and stimulation of XPC repair activity. Mol. Cell. Biol. 1997, 17:6924-6931.
25. van der Spek P.J., Eker A., Rademakers S., Visser C., Sugasawa K., Masutani C., Hanaoka F., Bootsma D., Hoeijmakers J.H. XPC and human homologs of RAD23: intracellular localization and relationship to other nucleotide excision repair complexes. Nucleic Acids Res. 1996, 24:2551-2559.
26. Wang D., Lippard S.J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 2005, 4:307-320.
27. Wang H.F., Chuang S.M., Hsiao C.C., Cherng S.H. A synergistic effect of GABA tea and copper(II) on DNA breakage in human peripheral lymphocytes. Food Chem. Toxicol. 2011, 49:955-962.
28. Welsh C., Day R., McGurk C., Masters J.R., Wood R.D., Koberle B. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int. J. Cancer 2004, 110:352-361.
29. Wu X., Fan W., Xu S., Zhou Y. Sensitization to the cytotoxicity of cisplatin by transfection with nucleotide excision repair gene xeroderma pigmentosum group A antisense RNA in human lung adenocarcinoma cells. Clin. Cancer Res. 2003, 9:5874-5879.
30. Zhu Q., Wani G., Wani M.A., Wani A.A. Human homologue of yeast Rad23 protein A interacts with p300/cyclic AMP-responsive element binding (CREB)-binding protein to down-regulate transcriptional activity of p53. Cancer Res. 2001, 61:64-70.